Clinician's Guide to Spinal Muscular Atrophy

Jump to:
Medical advisors icon

Meet our

Medical advisors

Edward Smith, M.D.

Edward Smith, MD

Melissa Wright, MD, PhD

SMA Pathophysiology

Written by Margaret Anne Rockwood | Last updated July 6th, 2026
✅ Medically reviewed by Edward Smith, MD

 

A hereditary neurodegenerative disorder, spinal Muscular Atrophy (SMA) is characterized by progressive weakness and atrophy of skeletal muscles. Its pathophysiology centers on a deficiency of the SMN protein, leading to widespread cellular dysfunction that disproportionately affects motor neurons. This deficiency impairs RNA splicing, axonal transport, and neuromuscular junction maintenance, leading to selective degeneration of lower motor neurons.

Prior to the advent of disease-modifying therapies (DMTs), SMA was one of the most common genetic causes of infant mortality and had been associated with severe disability and shortened lifespan. Advances in molecular genetics over the past three decades have transformed understanding of SMA from a clinically defined syndrome into a well-characterized disorder of RNA processing and motor neuron biology and have driven effective disease-modifying therapies.

The Role of SMN1 and SMN2

SMA is inherited in an autosomal recessive pattern caused primarily by mutations or deletions in the survival motor neuron 1 (SMN1) gene located on chromosome 5q13. In approximately 95% of patients, the disorder results from homozygous deletion of exon 7 in SMN1. The remaining cases typically involve compound heterozygous mutations, including point mutations in one allele and deletion in the other.

Without adequate SMN protein produced by SMN1, the body is deprived of what it needs to fuel neuromuscular maintenance and growth.

While most cases of SMA are caused by biallelic loss or dysfunction of the SMN1 gene, a related gene, SMN2, produces functional survival motor neuron protein, albeit only at about 10% the level of the SMN1 gene. Nevertheless, this reduced amount of SMN protein is sufficient to modify disease severity: more SMN2 copies generally correlate with milder disease, although the relationship is not perfect.

SMN2 is nearly identical to SMN1, differing by a critical single nucleotide substitution in exon 7. Although this substitution does not alter the amino acid sequence, it disrupts an exonic splicing enhancer, causing most SMN2 transcripts to exclude exon 7 during mRNA splicing. As a result, approximately 90% of SMN2-derived protein is truncated, unstable, and rapidly degraded. Only about 10% of transcripts produce functional full-length SMN protein.

Individuals with fewer SMN2 copies generally produce less functional SMN protein and therefore exhibit more severe phenotypes. For example, infants with SMA Type I often possess only two SMN2 copies, whereas individuals with milder forms such as SMA Type III or IV may carry three to five copies.

SMN Protein’s Critical Spliceosome Function

The SMN protein is ubiquitously expressed and essential for cellular survival. It is responsible for assembling small nuclear ribonucleoproteins (snRNPs), which are crucial components of the spliceosome. The spliceosome mediates pre-mRNA splicing, which generates mature messenger RNA from precursor transcripts.

SMN protein forms a multiprotein complex with Gemins, which facilitates snRNP biogenesis. Deficiency of SMN protein disrupts spliceosomal assembly and alters RNA processing in multiple tissues.

Although all cells require SMN protein, motor neurons are especially vulnerable to reductions in SMN levels.

Beyond RNA splicing, the SMN protein also participates in:

  • axonal mRNA transport
  • cytoskeletal organization
  • neuromuscular junction maintenance
  • local protein translation within axons
  • endocytosis and vesicle trafficking

These diverse functions help explain why SMN protein deficiency produces broad neuromuscular dysfunction despite a single gene defect.

Impact of SMN Protein Loss on Cellular and Molecular Function

Defective RNA Splicing

Considering that the SMN protein is essential for spliceosome assembly, reduced levels produce widespread splicing abnormalities. Numerous transcripts that are important for neuronal survival become improperly processed. Some of the genes they affect regulate:

  • axonal growth
  • synaptic function
  • cytoskeletal stability
  • cellular stress responses

Axonal Transport Dysfunction

Motor neurons rely on microtubule-dependent transport systems to move proteins, organelles, and RNA over long distances. SMN protein deficiency further impairs axonal trafficking by disrupting these dynamics and motor protein interactions in cytoskeletal cells, in particular. This disruption leads to the accumulation of “junk” cellular components in proximal axons and, as a consequence, inadequate delivery of essential materials to distal synapses.

Defective axonal transport contributes to:

  • axonal degeneration
  • synaptic failure
  • impaired regeneration
  • progressive denervation of muscle fibers

Neuromuscular Junction Abnormalities

The neuromuscular junction is an early and crucial site of SMA pathology. Studies in animal models reveal immature endplates, reduced synaptic capabilities and impaired neurotransmitter release, all before overt neuron loss is observed.

Denervation causes muscle fibers to lose trophic support and contractile stimulation. Consequently, muscle tissue undergoes progressive atrophy, fibrosis, and fatty replacement. These changes underlie the clinical manifestations of weakness and reduced motor function.

Pathological Muscle Cell Function

Although SMA is traditionally classified as a motor neuron disease, SMN protein deficiency within muscle cells can impair myogenesis, mitochondrial metabolism, and regenerative capacity.

Muscle biopsies in SMA often demonstrate:

  • grouped atrophy
  • fiber type grouping
  • small angular fibers
  • increased connective tissue

These findings reflect chronic denervation and re-innervation processes.

Selective Vulnerability of Motor Neurons

SMA researchers have probed why a ubiquitously expressed protein deficiency primarily damages alpha motor neurons. They have discovered several reasons that likely account for this selective vulnerability. A few highlights:

  • Size and length of motor neurons require higher efficiency: Motor neurons are exceptionally large and highly polarized cells with long axons. They depend more heavily on efficient intracellular transport and localized protein synthesis, supported by intact RNA metabolism and cytoskeletal organization. Reduced SMN protein levels impair transport of mRNA and ribonucleoprotein complexes along axons, leading to defective synaptic maintenance and axonal degeneration.
  • Genesis of SMA in the neuromuscular junctions: In SMA, abnormalities are detectable at neuromuscular junctions (NMJs) before significant motor neuron loss occurs. Immature or denervated NMJs exhibit impaired neurotransmission, reduced synaptic vesicle release, and altered acetylcholine receptor clustering. These synaptic defects contribute to early muscle weakness and may initiate a “dying-back” pattern of neurodegeneration in which distal axonal terminals degenerate before motor neuron cell bodies.
  • Motor neurons are more vulnerable to injury: Motor neurons also have increased susceptibility to oxidative stress, mitochondrial dysfunction, and impaired calcium homeostasis when the SMN protein is deficient. Disruption of these pathways activates apoptotic signaling and contributes to progressive neuronal death.

Systemic Manifestations of SMA

Despite the predominance of neuromuscular symptoms, SMA presents with multisystem manifestations. SMN protein deficiency affects multiple organ systems, particularly in severe infantile forms, but to some degree in all SMA cases.

Systemic abnormalities may include:

  • respiratory compromise
  • cardiac defects
  • gastrointestinal dysmotility
  • metabolic disturbances
  • pancreatic dysfunction
  • vascular abnormalities
  • bone density loss

While most of these abnormalities cause only mild symptoms, respiratory insufficiency is an exception, historically representing the leading cause of death in severe SMA Type I. Weakness of intercostal muscles and the diaphragm can lead to impaired cough mechanics, predisposing many patients to recurrent pulmonary infections, hypoventilation, and respiratory failure.

A Targetable Disease

Overall, the pathophysiology of SMA illustrates the profound consequences that disturbances in RNA metabolism can exert on neuronal survival. However, advances in molecular understanding have transformed SMA from a fatal childhood disease into one of the leading success stories of precision medicine. This is in large part because of the exon 7 deletion in SMN1 and because the presence or absence of sufficient compensation from SMN2 in SMA was isolated as a cause – and not confounded by other genetic aberrations, as is the case in most rare genetic diseases.

Advocacy has also played a key role in supporting the research enabling the gene therapies that are now significantly extending life for people with SMA.

Sources